Bank of America set a €95.00 ($110.47) price objective on Bayer (FRA:BAYN) in a research report report published on Friday, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.
A number of other research firms have also recently weighed in on BAYN. Deutsche Bank set a €70.00 ($81.40) target price on shares of Bayer and gave the company a neutral rating in a research note on Friday, August 9th. Warburg Research set a €61.00 ($70.93) target price on shares of Bayer and gave the company a neutral rating in a research note on Wednesday, August 21st. Sanford C. Bernstein set a €90.00 ($104.65) target price on shares of Bayer and gave the company a buy rating in a research note on Friday, August 9th. UBS Group set a €110.00 ($127.91) target price on shares of Bayer and gave the company a buy rating in a research note on Thursday, September 5th. Finally, JPMorgan Chase & Co. reissued a neutral rating on shares of Bayer in a research note on Tuesday, August 20th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of €80.82 ($93.97).
FRA BAYN opened at €67.87 ($78.92) on Friday. The company’s 50-day simple moving average is €63.50 and its 200 day simple moving average is €61.05. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: What is Elliott Wave theory?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.